We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vertex Q3 Earnings Call Highlights Revenue Beat and Pipeline Expansion
Read MoreHide Full Article
Key Takeaways
Vertex's Q3 revenues rise 12% to $3.44 billion, beating estimates, while earnings miss amid higher costs.
VRTX raises its 2026 revenue outlook to $13.15-$13.25 billion, including $40-$50 million from PALSONIFY.
Vertex expands its renal and endocrine pipeline, with a key FDA decision on povetacicept due Nov. 30.
Vertex Pharmaceuticals Incorporated (VRTX - Free Report) reported double-digit revenue growth in the third quarter of 2026, supported by its cystic fibrosis (CF) franchise and increasing contributions from newer therapies. However, higher operating expenses and acquisition-related financing costs weighed on profitability.
The company raised its full-year revenue guidance following the acquisition of Crinetics Pharmaceuticals, which expanded its commercial presence into rare endocrine diseases.
VRTX Q3 Earnings Miss Estimates, Revenue Beat
Vertex reported third-quarter 2026 non-GAAP earnings of $4.76 per share, which missed the Zacks Consensus Estimate of $4.92 by 3.25%. Earnings declined from $4.80 per share in the year-ago quarter.
Quarterly revenues were $3.44 billion, surpassing the Zacks Consensus Estimate of $3.40 billion by approximately 1.2%. Revenues increased 12% year over year, reflecting growth in CF treatments and expanding contributions from CASGEVY and JOURNAVX.
Vertex Pharmaceuticals Incorporated Price, Consensus and EPS Surprise
Vertex's CF franchise generated approximately $3.27 billion in third-quarter revenues, increasing 8% year over year. ALYFTREK contributed $706 million, benefiting from patient conversions, expanded reimbursement and growing international adoption.
CASGEVY revenues reached $99 million, up 30% sequentially, supported by increasing patient infusions. JOURNAVX generated $58 million, an 18% sequential improvement, while prescriptions surpassed 750,000 during the quarter.
PALSONIFY contributed $10 million following the September completion of the Crinetics acquisition, providing an additional source of commercial revenue.
Vertex Raises 2026 Revenue Guidance
Vertex increased its full-year 2026 revenue forecast to $13.15-$13.25 billion from $13.1-$13.2 billion. The revised outlook includes an anticipated $40-$50 million contribution from PALSONIFY.
Management maintained its expectation of generating at least $500 million in combined revenues from CASGEVY and JOURNAVX during 2026.
However, the company increased its combined non-GAAP operating expense forecast to approximately $6 billion from $5.65-$5.75 billion, primarily reflecting Crinetics integration expenses and investments supporting commercial launches.
VRTX Advances Renal and Endocrine Pipeline
Vertex highlighted the upcoming regulatory decision for povetacicept in immunoglobulin A nephropathy, with the FDA's target action date scheduled for Nov. 30, 2026. Potential approval would establish nephrology as another commercial franchise.
Management also expects interim results from the AMPLITUDE study of inaxaplin in early 2027, alongside additional clinical milestones in neuropathic pain and rare endocrine disorders.
In type 1 diabetes, Vertex is prioritizing VX-017, with plans to advance the investigational cell therapy into pivotal development in 2027.
Acquisition Costs Weigh on Vertex's Profitability
Despite higher revenues, Vertex's GAAP net income declined to approximately $654 million from $1.08 billion a year earlier, primarily reflecting expenses associated with the Crinetics acquisition.
Non-GAAP research and development expenses rose 9% to approximately $936 million, while non-GAAP selling, general and administrative expenses climbed 51% to $556 million.
Vertex ended the September quarter with approximately $9.8 billion in cash and investments, providing financial flexibility for pipeline investments and commercial expansion. Nevertheless, higher financing expenses and integration costs could continue affecting near-term earnings.
Management's strategy remains focused on strengthening the established CF franchise while developing additional revenue streams across hematology, pain, endocrinology and renal diseases. The success of these initiatives will depend on commercial adoption, regulatory outcomes and disciplined expense management.
View the Zacks #1 Rank List
Image: Bigstock
Vertex Q3 Earnings Call Highlights Revenue Beat and Pipeline Expansion
Key Takeaways
Vertex Pharmaceuticals Incorporated (VRTX - Free Report) reported double-digit revenue growth in the third quarter of 2026, supported by its cystic fibrosis (CF) franchise and increasing contributions from newer therapies. However, higher operating expenses and acquisition-related financing costs weighed on profitability.
The company raised its full-year revenue guidance following the acquisition of Crinetics Pharmaceuticals, which expanded its commercial presence into rare endocrine diseases.
VRTX Q3 Earnings Miss Estimates, Revenue Beat
Vertex reported third-quarter 2026 non-GAAP earnings of $4.76 per share, which missed the Zacks Consensus Estimate of $4.92 by 3.25%. Earnings declined from $4.80 per share in the year-ago quarter.
Quarterly revenues were $3.44 billion, surpassing the Zacks Consensus Estimate of $3.40 billion by approximately 1.2%. Revenues increased 12% year over year, reflecting growth in CF treatments and expanding contributions from CASGEVY and JOURNAVX.
Vertex Pharmaceuticals Incorporated Price, Consensus and EPS Surprise
Vertex Pharmaceuticals Incorporated price-consensus-eps-surprise-chart | Vertex Pharmaceuticals Incorporated Quote
Vertex currently carries a Zacks Rank #3 (Hold). Its Value Score is D, Growth Score is C, Momentum Score is B and VGM Score is C. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
VRTX Sees Growth Across Commercial Franchises
Vertex's CF franchise generated approximately $3.27 billion in third-quarter revenues, increasing 8% year over year. ALYFTREK contributed $706 million, benefiting from patient conversions, expanded reimbursement and growing international adoption.
CASGEVY revenues reached $99 million, up 30% sequentially, supported by increasing patient infusions. JOURNAVX generated $58 million, an 18% sequential improvement, while prescriptions surpassed 750,000 during the quarter.
PALSONIFY contributed $10 million following the September completion of the Crinetics acquisition, providing an additional source of commercial revenue.
Vertex Raises 2026 Revenue Guidance
Vertex increased its full-year 2026 revenue forecast to $13.15-$13.25 billion from $13.1-$13.2 billion. The revised outlook includes an anticipated $40-$50 million contribution from PALSONIFY.
Management maintained its expectation of generating at least $500 million in combined revenues from CASGEVY and JOURNAVX during 2026.
However, the company increased its combined non-GAAP operating expense forecast to approximately $6 billion from $5.65-$5.75 billion, primarily reflecting Crinetics integration expenses and investments supporting commercial launches.
VRTX Advances Renal and Endocrine Pipeline
Vertex highlighted the upcoming regulatory decision for povetacicept in immunoglobulin A nephropathy, with the FDA's target action date scheduled for Nov. 30, 2026. Potential approval would establish nephrology as another commercial franchise.
Management also expects interim results from the AMPLITUDE study of inaxaplin in early 2027, alongside additional clinical milestones in neuropathic pain and rare endocrine disorders.
In type 1 diabetes, Vertex is prioritizing VX-017, with plans to advance the investigational cell therapy into pivotal development in 2027.
Acquisition Costs Weigh on Vertex's Profitability
Despite higher revenues, Vertex's GAAP net income declined to approximately $654 million from $1.08 billion a year earlier, primarily reflecting expenses associated with the Crinetics acquisition.
Non-GAAP research and development expenses rose 9% to approximately $936 million, while non-GAAP selling, general and administrative expenses climbed 51% to $556 million.
Vertex ended the September quarter with approximately $9.8 billion in cash and investments, providing financial flexibility for pipeline investments and commercial expansion. Nevertheless, higher financing expenses and integration costs could continue affecting near-term earnings.
Management's strategy remains focused on strengthening the established CF franchise while developing additional revenue streams across hematology, pain, endocrinology and renal diseases. The success of these initiatives will depend on commercial adoption, regulatory outcomes and disciplined expense management.